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Background:  Percutaneous ventricular assist devices (pVAD’s) are being increasingly used in advanced circulatory support. We sought to evaluate 
the efficacy of pVAD implantation for circulatory support in an extremely high-risk cohort of patients with severe refractory cardiogenic shock (SRCS) 
undergoing cardiopulmonary resuscitation (CPR).
Methods:  TandemHeart® pVAD was percutaneously implanted in 56 patients undergoing CPR just before or at the time of implantation. Changes 
in hemodynamic and biochemical markers were assessed pre cardiac arrest and at 24 hours after pVAD implantation and were compared for 
statistical significance using non-parametric tests to adjust for non-normal distribution. Results are reported in medians and interquartile ranges 
(IQR).
Results:  Survival after pVAD implantation at 24 hrs, 30 days and 6 months was 82.1%, 41.1% and 33.9%. Mean Arterial Pressure (MAP) after 
pVAD implantation was 80 (IQR 15) mm Hg, while cardiac index was 3.1 (IQR 0.8) L/min/m2. Urine output significantly increased from 20 (IQR 40) 
to 72.50 (IQR 57.5) ml/hr, p < 0.001. Lactic acid decreased from 91 (IQR 111) to 21.5 (IQR 23.73), p = 0.001, while pH increased from 7.29 (IQR 
0.24) to 7.45 (IQR 0.11), p < 0.001. Serum creatinine changed from 1.65 (IQR 1.08) to 1.8 (IQR 1.4), p = 0.840, mixed venous oxygen changed 
from 40.5 (IQR 45) to 65.9 (IQR 12.75), p = 0.592 and LDH from 672 (IQR 1905) to 918.5 (IQR 516.75), p = 0.848.
Conclusions:  TandemHeart® pVAD provides adequate circulatory support in SRCS patients undergoing CPR as evidenced by significant 
improvement in the hemodynamic and biochemical parameters, and improves survival in this extremely high risk cohort, wherein survival without 
mechanical support approaches zero.
